Bivalirudin in PCI: An Overview of the REPLACE-2 Trial

The Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE)-2 trial is one of the largest acute randomized controlled trials evaluating the efficacy of two anticoagulant strategies during contemporary urgent or elective percutaneous coronary intervention (PCI). The direct thrombin inhibitor, bivalirudin, with provisional use of glycoprotein IIb/IIIa (GP IIb/IIIa) inhibitor was compared to low-dose unfractionated heparin (UFH) plus planned GP IIb/IIIa inhibitor. At 30-day follow-up, the primary quadruple composite endpoint (death, myocardial infarction (MI), urgent repeat revascularization, or in-hospital major bleeding) occurred in 9.2% of patients in the bivalirudin group versus 10.0% of patients in the UFH plus GP IIb/IIIa inhibitor group. The secondary triple composite endpoint (death, MI, urgent repeat revascularization) occurred in 7.6% of patients in the bivalirudin group compared with 7.1% of patients in the UFH plus GP IIb/IIIa inhibitor group. Both endpoints met formal statistical criteria for noninferiority to UFH plus GP IIb/IIIa inhibitor. By imputed comparison from historic GP IIb/IIIa trials between bivalirudin versus UFH alone, REPLACE-2 demonstrated that bivalirudin was superior to UFH alone with respect to the quadruple and triple composite endpoints. Furthermore, bivalirudin plus provisional GP IIb/IIIa blockade was associated with a significant reduction in in-hospital bleeding (2.4% vs. 4.1%; p < 0.001). At 6 months' follow-up, there was no significant difference in rates of death, MI, or revascularization between the two groups. Furthermore, there was no evidence that the early, nonsignificant 0.5% excess non-Q-wave MI in the bivalirudin group translated into later mortality. There was a trend toward decreased mortality at 6 months in the bivalirudin arm (0.95% vs. 1.35%; p = 0.148). The relative efficacy of bivalirudin versus UFH plus GP IIb/IIIa inhibitor was similar in several high-risk subgroups, including patients with diabetes mellitus or prior MI, women, the elderly (age > 65 years), and patients undergoing PCI of bypass grafts. Bivalirudin represents an exciting alternative to UFH plus GP IIb/IIIa inhibitor in patients undergoing urgent and elective PCI with similar suppression of ischemic events, fewer bleeding complications, and the potential for greater cost savings and ease of administration.

KEYWORDS

REPLACE-2 - bivalirudin - heparin - glycoprotein (GP) inhibitors - percutaneous coronary interventions - PCI

REFERENCES

• 1 Lincoff A M, Califf R M, Topol E J. Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease.  J Am Coll Cardiol. 2000;  35 1103-1115
• 2 Anderson K M, Califf R M, Stone G W et al.. Long-term mortality benefit with abciximab in patients undergoing percutaneous coronary intervention.  J Am Coll Cardiol. 2001;  37 2059-2065
• 3 Bittl J A, Chaitman B R, Feit F, Kimball W, Topol E J. Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: final report reanalysis of the Bivalirudin Angioplasty Study.  Am Heart J. 2001;  142 952-959
• 4 Lincoff A M, Kleiman N S, Kottke-Marchant K et al.. Bivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during percutaneous coronary revascularization: results of the Comparison of Abciximab Complications with Hirulog for Ischemic Events Trial (CACHET).  Am Heart J. 2002;  143 847-853
• 5 Lincoff A M, Bittl J A, Kleiman N S. The REPLACE-1 trial: a pilot study of bivalirudin vs heparin during percutaneous coronary intervention with stenting and GP IIb/IIIa blockade.  Am J Cardiol. 2004;  93 1092-1096
• 6 Lincoff A M, Bittl J A, Harrington R A et al.. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial.  JAMA. 2003;  289 853-863
• 7 ESPRIT Investigators . Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial.  Lancet. 2000;  356 2037-2044
• 8 EPISTENT Investigators . Evaluation of platelet IIb/IIIa inhibitor for stenting. randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade.  Lancet. 1998;  352 87-92
• 9 Brener S J, Lytle B W, Schneider J P, Ellis S G, Topol E J. Association between CK-MB elevation after percutaneous or surgical revascularization and three-year mortality.  J Am Coll Cardiol. 2002;  40 1961-1967
• 10 Cohen D J, Lavelle T, Chen H-L et al.. Cost-effectiveness of bivalirudin with provisional glycoprotein 2b/3a inhibition vs. heparin + routine glycoprotein 2b/3a inhibition for contemporary PCU: results from the REPLACE II trial.  Circulation. 2003;  108(suppl IV) IV-570
• 11 Brener S J, Barr L A, Burchenal J E et al.. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators.  Circulation. 1998;  98 734-741
• 12 Montalescot G, Barragan P, Wittenberg O et al.. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction.  N Engl J Med. 2001;  344 1895-1903
• 13 Neumann F J, Kastrati A, Schmitt C et al.. Effect of glycoprotein IIb/IIIa receptor blockade with abciximab on clinical and angiographic restenosis rate after the placement of coronary stents following acute myocardial infarction.  J Am Coll Cardiol. 2000;  35 915-921
• 14 Bhatt D L, Marso S P, Lincoff A M, Wolski K E, Ellis S G, Topol E J. Abciximab reduces mortality in diabetics following percutaneous coronary intervention.  J Am Coll Cardiol. 2000;  35 922-928
• 15 Kereiakes D J, Lincoff A M, Anderson K M et al.. Abciximab survival advantage following percutaneous coronary intervention is predicted by clinical risk profile.  Am J Cardiol. 2002;  90 628-630